In yesterday’s Wall Street session, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares traded at $1.94, down -1.52% from the previous session.
As of this writing, 4 analysts cover Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $3.00, we find $8.00. Given the previous closing price of $1.97, this indicates a potential upside of 306.09 percent. LXRX stock price is now -23.68% away from the 50-day moving average and -17.19% away from the 200-day moving average. The market capitalization of the company currently stands at $479.59M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 2 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target of $3, Jefferies recently initiated with Hold rating for Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).
In other news, COATS LONNEL, Chief Executive Officer bought 10,000 shares of the company’s stock on Jun 29. The stock was bought for $21,600 at an average price of $2.16. Upon completion of the transaction, the Chief Executive Officer now directly owns 814,359 shares in the company, valued at $1.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 26, Chief Executive Officer COATS LONNEL bought 10,000 shares of the business’s stock. A total of $21,792 was incurred on buying the stock at an average price of $2.18. This leaves the insider owning 804,359 shares of the company worth $1.56 million. Insiders disposed of 178,167 shares of company stock worth roughly $0.35 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LXRX stock. A new stake in Lexicon Pharmaceuticals Inc. shares was purchased by NATIXIS ADVISORS, L.P. during the first quarter worth $170,000. GSA CAPITAL PARTNERS LLP invested $135,000 in shares of LXRX during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in Lexicon Pharmaceuticals Inc. valued at approximately $118,000. CAPTRUST FINANCIAL ADVISORS acquired a new stake in LXRX for approximately $90,000. VIRTU FINANCIAL LLC purchased a new stake in LXRX valued at around $42,000 in the second quarter. In total, there are 155 active investors with 82.30% ownership of the company’s stock.
Wednesday morning saw Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) opened at $1.9700. During the past 12 months, Lexicon Pharmaceuticals Inc. has had a low of $1.71 and a high of $3.79. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.40, and a quick ratio of 5.40. The fifty day moving average price for LXRX is $2.5236 and a two-hundred day moving average price translates $2.3402 for the stock.
The latest earnings results from Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.17, beating analysts’ expectations of -$0.18 by 0.01. This compares to -$0.16 EPS in the same period last year. The company reported revenue of $24000.0 for the quarter, compared to $37000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -35.14 percent. For the current quarter, analysts expect LXRX to generate $70k in revenue.
Lexicon Pharmaceuticals Inc.(LXRX) Company Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
